By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Neumedicines Inc. 

2708 Foothill Boulevard
Suite 403
La Crescenta  California  91214  U.S.A.
Phone: 818-606-2638 Fax: 818-293-0267


SEARCH JOBS


Industry
Biotechnology






Company News
Neumedicines Inc. Names David L. Morash President And Chief Strategy Officer 9/17/2014 9:57:08 AM
Phase I Clinical Study Of Neumedicines Inc.' Interleukin-12 As A Treatment For Wound Healing And Infections Recommended For Funding By The U.S. Department Of Defense 4/28/2014 11:06:14 AM
Neumedicines Inc. To Feature HemaMax Study Results In Presentation At Biotech Showcase Conference 1/9/2014 9:58:37 AM
Neumedicines Inc.’ Study Shows HemaMax, Not Neupogen (G-CSF), Improves Survival Outcomes Following Lethal Irradiation 1/8/2014 9:06:43 AM
Neumedicines Inc. Joins The Alliance For Biosecurity 1/2/2014 9:00:39 AM
Neumedicines Inc. Presents HemaMax™ Clinical Data At The American Society of Hematology Conference 12/16/2013 9:26:40 AM
Neumedicines Inc. Presents HemaMax™ Clinical Data At The American Society of Hematology Conference 12/13/2013 7:15:53 AM
Neumedicines Inc. Receives an Award of $8.3 Million From Biomedical Advanced Research and Development Authority (BARDA) for Continued Development of HemaMax as a Countermeasure to Acute Radiation Exposure 6/10/2013 10:03:12 AM
Neumedicines Inc. Receives Biomedical Advanced Research and Development Authority (BARDA) Notification of Intent to Exercise Contract Option to Continue Development of HemaMax as Radiation Medical Countermeasure 5/14/2013 10:06:31 AM
Neumedicines Inc. Wins U.S. Federal Government Contract for up to $273 Million to Fund Late-Stage Development of HemaMax(TM), a Novel Radiation Medical Countermeasure 9/26/2011 10:28:21 AM
12
//-->